AI
AI
AI
ArcaScience raises $7M to expand AI benefit risk platform in drug development
French artificial intelligence healthtech startup ArcaScience SAS revealed today that it has raised $7 million in new funding to expand into the U.S. and the U.K., launch a patient-facing solution for pediatric brain cancer and dermatological diseases,and hire a chief medical officer.
Founded in 2018, ArcaScience is an AI-first healthtech startup that has been built on a mission of “enabling better and safer drugs.” The company aims to harness the power of biomedical knowledge, structured and unstructured, to support smarter decision-making across the pharmaceutical value chain.
ArcaScience uses AI to transform massive volumes of biomedical data into actionable benefit-risk insights. The company’s platform integrates more than 100 billion biomedical data points and employs multiple specialized AI models to rapidly assess the risk-benefit profiles of drug candidates.
The net result is that evaluations that usually take months, or even longer, can now be computed in mere seconds, dramatically accelerating drug development timelines.
ArcaScience’s solution tackles a critical problem in drug development – the inability to fully leverage biomedical data. According to the company, up to 90% of valuable data often remains unused due to its siloed or unstructured nature. ArcaScience bridges this gap by federating disparate data sources, from clinical studies to real-world evidence to extract key indicators such as adverse events, biomarkers, patient profiles, toxicity measures and patent information.
“It takes 10+ years to bring a drug to market. There is a 90% fail rate and the average cost per drug that makes it to the market is $2.3bn!,” explains Romain Clement, founder and chief executive officer at ArcaScience. “Benefit-risk prediction is no longer a nice-to-have, but a prerequisite for building better drugs.”
The company’s platform is already being adopted by major pharma companies, including Sanofi S.A., AstraZeneca plc, GSK plc and Takeda Pharmaceutical Company Ltd. and research institutions including the Paris Brain Institute, to optimize clinical operations, pharmacovigilance, and strategic decision-making.
The seed round was led by The Moon Venture, with Pléiade Venture SAS, Plug&Play Ventures, Bpifrance SA and AKKA Technologies SE also participating.
Photo: ArcaScience
A message from John Furrier, co-founder of SiliconANGLE:
Support our mission to keep content open and free by engaging with theCUBE community. Join theCUBE’s Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities.
- 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more
- 11.4k+ theCUBE alumni — Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network.
About SiliconANGLE Media
SiliconANGLE Media is a recognized leader in digital media innovation, uniting breakthrough technology, strategic insights and real-time audience engagement. As the parent company of SiliconANGLE, theCUBE Network, theCUBE Research, CUBE365, theCUBE AI and theCUBE SuperStudios — with flagship locations in Silicon Valley and the New York Stock Exchange — SiliconANGLE Media operates at the intersection of media, technology and AI.
Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Our new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations.
